Solasia Pharma K.K. (TYO:4597)

Market Cap	6.98B
Revenue (ttm)	316.00M
Net Income (ttm)	-1.94B
Shares Out	218.05M
EPS (ttm)	-9.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,284,000
Average Volume	4,666,755
Open	33.00
Previous Close	33.00
Day's Range	31.00 - 33.00
52-Week Range	25.00 - 70.00
Beta	1.31
RSI	44.26
Earnings Date	May 14, 2025

About Solasia Pharma K.K.

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting. It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer. Th...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 23
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4597

Financial Performance

In 2024, Solasia Pharma K.K.'s revenue was 316.00 million, a decrease of -48.78% compared to the previous year's 617.00 million. Losses were -1.94 billion, 74.6% more than in 2023.